title: Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer.
abstract: OBJECTIVE
  TH-302 is an investigational hypoxia-activated prodrug that releases the DNA alkylator bromo-isophosphoramide mustard in hypoxic settings. This phase II study (NCT01144455) evaluated gemcitabine plus TH-302 in patients with previously untreated, locally advanced or metastatic pancreatic cancer.
  
  
  METHODS
  Patients were randomly assigned 1:1:1 to gemcitabine (1,000 mg/m(2)), gemcitabine plus TH-302 240 mg/m(2) (G+T240), or gemcitabine plus TH-302 340 mg/m(2) (G+T340). Randomized crossover after progression on gemcitabine was allowed. The primary end point was progression-free survival (PFS). Secondary end points included overall survival (OS), tumor response, CA 19-9 response, and safety.
  
  
  RESULTS
  Two hundred fourteen patients (77% with metastatic disease) were enrolled between June 2010 and July 2011. PFS was significantly longer with gemcitabine plus TH-302 (pooled combination arms) compared with gemcitabine alone (median PFS, 5.6 v 3.6 months, respectively; hazard ratio, 0.61; 95% CI, 0.43 to 0.87; P = .005; median PFS for metastatic disease, 5.1 v 3.4 months, respectively). Median PFS times for G+T240 and G+T340 were 5.6 and 6.0 months, respectively. Tumor response was 12%, 17%, and 26% in the gemcitabine, G+T240, and G+T340 arms, respectively (G+T340 v gemcitabine, P = .04). CA 19-9 decrease was greater with G+T340 versus gemcitabine (-5,398 v -549 U/mL, respectively; P = .008). Median OS times for gemcitabine, G+T240, and G+T340 were 6.9, 8.7, and 9.2 months, respectively (P = not significant). The most common adverse events (AEs) were fatigue, nausea, and peripheral edema (frequencies similar across arms). Skin and mucosal toxicities (2% grade 3) and myelosuppression (55% grade 3 or 4) were the most common TH-302-related AEs but were not associated with treatment discontinuation.
  
  
  CONCLUSIONS
  PFS, tumor response, and CA 19-9 response were significantly improved with G+TH-302. G+T340 is being investigated further in the phase III MAESTRO study (NCT01746979).
authors.affiliation: Mitesh J. Borad, Mayo Clinic, Scottsdale; Tomislav Dragovich, Arizona Cancer Center, Tucson, AZ; Shantan G. Reddy, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA; Nathan Bahary, University of Pittsburgh Medical Center, Pittsburgh, PA; Hope E. Uronis, Duke University Medical Center, Durham, NC; Darren Sigal, Scripps Clinic, La Jolla; Peter J. Rosen, Disney Family Cancer Center, Burbank; Clarence Eng and Stew Kroll, Threshold Pharmaceuticals, South San Francisco, CA; Allen L. Cohn, Rocky Mountain Cancer Center, Denver, CO; William R. Schelman, University of Wisconsin Carbone Cancer Center, Madison, WI; Joe Stephenson Jr, Institute for Translational Oncology Research, Greenville, SC; E. Gabriela Chiorean, Indiana University Simon Cancer Center, Indianapolis, IN; Brian Ulrich, Texas Oncology, Wichita Falls, TX; Salvatore A. Del Prete, Hematology Oncology PC, Stamford, CT; Mark Rarick, Kaiser Permanente Northwest Region Oncology Hematology, Portland, OR; and David P. Ryan, Massachusetts General Hospital Cancer Center, Boston, MA. Borad.mitesh@mayo.edu.
authors.forename: Mitesh J
authors.initials: MJ
authors.lastname: Borad
authors.affiliation: Mitesh J. Borad, Mayo Clinic, Scottsdale; Tomislav Dragovich, Arizona Cancer Center, Tucson, AZ; Shantan G. Reddy, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA; Nathan Bahary, University of Pittsburgh Medical Center, Pittsburgh, PA; Hope E. Uronis, Duke University Medical Center, Durham, NC; Darren Sigal, Scripps Clinic, La Jolla; Peter J. Rosen, Disney Family Cancer Center, Burbank; Clarence Eng and Stew Kroll, Threshold Pharmaceuticals, South San Francisco, CA; Allen L. Cohn, Rocky Mountain Cancer Center, Denver, CO; William R. Schelman, University of Wisconsin Carbone Cancer Center, Madison, WI; Joe Stephenson Jr, Institute for Translational Oncology Research, Greenville, SC; E. Gabriela Chiorean, Indiana University Simon Cancer Center, Indianapolis, IN; Brian Ulrich, Texas Oncology, Wichita Falls, TX; Salvatore A. Del Prete, Hematology Oncology PC, Stamford, CT; Mark Rarick, Kaiser Permanente Northwest Region Oncology Hematology, Portland, OR; and David P. Ryan, Massachusetts General Hospital Cancer Center, Boston, MA.
authors.forename: Shantan G
authors.initials: SG
authors.lastname: Reddy
authors.affiliation: Mitesh J. Borad, Mayo Clinic, Scottsdale; Tomislav Dragovich, Arizona Cancer Center, Tucson, AZ; Shantan G. Reddy, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA; Nathan Bahary, University of Pittsburgh Medical Center, Pittsburgh, PA; Hope E. Uronis, Duke University Medical Center, Durham, NC; Darren Sigal, Scripps Clinic, La Jolla; Peter J. Rosen, Disney Family Cancer Center, Burbank; Clarence Eng and Stew Kroll, Threshold Pharmaceuticals, South San Francisco, CA; Allen L. Cohn, Rocky Mountain Cancer Center, Denver, CO; William R. Schelman, University of Wisconsin Carbone Cancer Center, Madison, WI; Joe Stephenson Jr, Institute for Translational Oncology Research, Greenville, SC; E. Gabriela Chiorean, Indiana University Simon Cancer Center, Indianapolis, IN; Brian Ulrich, Texas Oncology, Wichita Falls, TX; Salvatore A. Del Prete, Hematology Oncology PC, Stamford, CT; Mark Rarick, Kaiser Permanente Northwest Region Oncology Hematology, Portland, OR; and David P. Ryan, Massachusetts General Hospital Cancer Center, Boston, MA.
authors.forename: Nathan
authors.initials: N
authors.lastname: Bahary
authors.affiliation: Mitesh J. Borad, Mayo Clinic, Scottsdale; Tomislav Dragovich, Arizona Cancer Center, Tucson, AZ; Shantan G. Reddy, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA; Nathan Bahary, University of Pittsburgh Medical Center, Pittsburgh, PA; Hope E. Uronis, Duke University Medical Center, Durham, NC; Darren Sigal, Scripps Clinic, La Jolla; Peter J. Rosen, Disney Family Cancer Center, Burbank; Clarence Eng and Stew Kroll, Threshold Pharmaceuticals, South San Francisco, CA; Allen L. Cohn, Rocky Mountain Cancer Center, Denver, CO; William R. Schelman, University of Wisconsin Carbone Cancer Center, Madison, WI; Joe Stephenson Jr, Institute for Translational Oncology Research, Greenville, SC; E. Gabriela Chiorean, Indiana University Simon Cancer Center, Indianapolis, IN; Brian Ulrich, Texas Oncology, Wichita Falls, TX; Salvatore A. Del Prete, Hematology Oncology PC, Stamford, CT; Mark Rarick, Kaiser Permanente Northwest Region Oncology Hematology, Portland, OR; and David P. Ryan, Massachusetts General Hospital Cancer Center, Boston, MA.
authors.forename: Hope E
authors.initials: HE
authors.lastname: Uronis
authors.affiliation: Mitesh J. Borad, Mayo Clinic, Scottsdale; Tomislav Dragovich, Arizona Cancer Center, Tucson, AZ; Shantan G. Reddy, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA; Nathan Bahary, University of Pittsburgh Medical Center, Pittsburgh, PA; Hope E. Uronis, Duke University Medical Center, Durham, NC; Darren Sigal, Scripps Clinic, La Jolla; Peter J. Rosen, Disney Family Cancer Center, Burbank; Clarence Eng and Stew Kroll, Threshold Pharmaceuticals, South San Francisco, CA; Allen L. Cohn, Rocky Mountain Cancer Center, Denver, CO; William R. Schelman, University of Wisconsin Carbone Cancer Center, Madison, WI; Joe Stephenson Jr, Institute for Translational Oncology Research, Greenville, SC; E. Gabriela Chiorean, Indiana University Simon Cancer Center, Indianapolis, IN; Brian Ulrich, Texas Oncology, Wichita Falls, TX; Salvatore A. Del Prete, Hematology Oncology PC, Stamford, CT; Mark Rarick, Kaiser Permanente Northwest Region Oncology Hematology, Portland, OR; and David P. Ryan, Massachusetts General Hospital Cancer Center, Boston, MA.
authors.forename: Darren
authors.initials: D
authors.lastname: Sigal
authors.affiliation: Mitesh J. Borad, Mayo Clinic, Scottsdale; Tomislav Dragovich, Arizona Cancer Center, Tucson, AZ; Shantan G. Reddy, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA; Nathan Bahary, University of Pittsburgh Medical Center, Pittsburgh, PA; Hope E. Uronis, Duke University Medical Center, Durham, NC; Darren Sigal, Scripps Clinic, La Jolla; Peter J. Rosen, Disney Family Cancer Center, Burbank; Clarence Eng and Stew Kroll, Threshold Pharmaceuticals, South San Francisco, CA; Allen L. Cohn, Rocky Mountain Cancer Center, Denver, CO; William R. Schelman, University of Wisconsin Carbone Cancer Center, Madison, WI; Joe Stephenson Jr, Institute for Translational Oncology Research, Greenville, SC; E. Gabriela Chiorean, Indiana University Simon Cancer Center, Indianapolis, IN; Brian Ulrich, Texas Oncology, Wichita Falls, TX; Salvatore A. Del Prete, Hematology Oncology PC, Stamford, CT; Mark Rarick, Kaiser Permanente Northwest Region Oncology Hematology, Portland, OR; and David P. Ryan, Massachusetts General Hospital Cancer Center, Boston, MA.
authors.forename: Allen L
authors.initials: AL
authors.lastname: Cohn
authors.affiliation: Mitesh J. Borad, Mayo Clinic, Scottsdale; Tomislav Dragovich, Arizona Cancer Center, Tucson, AZ; Shantan G. Reddy, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA; Nathan Bahary, University of Pittsburgh Medical Center, Pittsburgh, PA; Hope E. Uronis, Duke University Medical Center, Durham, NC; Darren Sigal, Scripps Clinic, La Jolla; Peter J. Rosen, Disney Family Cancer Center, Burbank; Clarence Eng and Stew Kroll, Threshold Pharmaceuticals, South San Francisco, CA; Allen L. Cohn, Rocky Mountain Cancer Center, Denver, CO; William R. Schelman, University of Wisconsin Carbone Cancer Center, Madison, WI; Joe Stephenson Jr, Institute for Translational Oncology Research, Greenville, SC; E. Gabriela Chiorean, Indiana University Simon Cancer Center, Indianapolis, IN; Brian Ulrich, Texas Oncology, Wichita Falls, TX; Salvatore A. Del Prete, Hematology Oncology PC, Stamford, CT; Mark Rarick, Kaiser Permanente Northwest Region Oncology Hematology, Portland, OR; and David P. Ryan, Massachusetts General Hospital Cancer Center, Boston, MA.
authors.forename: William R
authors.initials: WR
authors.lastname: Schelman
authors.affiliation: Mitesh J. Borad, Mayo Clinic, Scottsdale; Tomislav Dragovich, Arizona Cancer Center, Tucson, AZ; Shantan G. Reddy, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA; Nathan Bahary, University of Pittsburgh Medical Center, Pittsburgh, PA; Hope E. Uronis, Duke University Medical Center, Durham, NC; Darren Sigal, Scripps Clinic, La Jolla; Peter J. Rosen, Disney Family Cancer Center, Burbank; Clarence Eng and Stew Kroll, Threshold Pharmaceuticals, South San Francisco, CA; Allen L. Cohn, Rocky Mountain Cancer Center, Denver, CO; William R. Schelman, University of Wisconsin Carbone Cancer Center, Madison, WI; Joe Stephenson Jr, Institute for Translational Oncology Research, Greenville, SC; E. Gabriela Chiorean, Indiana University Simon Cancer Center, Indianapolis, IN; Brian Ulrich, Texas Oncology, Wichita Falls, TX; Salvatore A. Del Prete, Hematology Oncology PC, Stamford, CT; Mark Rarick, Kaiser Permanente Northwest Region Oncology Hematology, Portland, OR; and David P. Ryan, Massachusetts General Hospital Cancer Center, Boston, MA.
authors.forename: Joe
authors.initials: J
authors.lastname: Stephenson
authors.affiliation: Mitesh J. Borad, Mayo Clinic, Scottsdale; Tomislav Dragovich, Arizona Cancer Center, Tucson, AZ; Shantan G. Reddy, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA; Nathan Bahary, University of Pittsburgh Medical Center, Pittsburgh, PA; Hope E. Uronis, Duke University Medical Center, Durham, NC; Darren Sigal, Scripps Clinic, La Jolla; Peter J. Rosen, Disney Family Cancer Center, Burbank; Clarence Eng and Stew Kroll, Threshold Pharmaceuticals, South San Francisco, CA; Allen L. Cohn, Rocky Mountain Cancer Center, Denver, CO; William R. Schelman, University of Wisconsin Carbone Cancer Center, Madison, WI; Joe Stephenson Jr, Institute for Translational Oncology Research, Greenville, SC; E. Gabriela Chiorean, Indiana University Simon Cancer Center, Indianapolis, IN; Brian Ulrich, Texas Oncology, Wichita Falls, TX; Salvatore A. Del Prete, Hematology Oncology PC, Stamford, CT; Mark Rarick, Kaiser Permanente Northwest Region Oncology Hematology, Portland, OR; and David P. Ryan, Massachusetts General Hospital Cancer Center, Boston, MA.
authors.forename: E Gabriela
authors.initials: EG
authors.lastname: Chiorean
authors.affiliation: Mitesh J. Borad, Mayo Clinic, Scottsdale; Tomislav Dragovich, Arizona Cancer Center, Tucson, AZ; Shantan G. Reddy, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA; Nathan Bahary, University of Pittsburgh Medical Center, Pittsburgh, PA; Hope E. Uronis, Duke University Medical Center, Durham, NC; Darren Sigal, Scripps Clinic, La Jolla; Peter J. Rosen, Disney Family Cancer Center, Burbank; Clarence Eng and Stew Kroll, Threshold Pharmaceuticals, South San Francisco, CA; Allen L. Cohn, Rocky Mountain Cancer Center, Denver, CO; William R. Schelman, University of Wisconsin Carbone Cancer Center, Madison, WI; Joe Stephenson Jr, Institute for Translational Oncology Research, Greenville, SC; E. Gabriela Chiorean, Indiana University Simon Cancer Center, Indianapolis, IN; Brian Ulrich, Texas Oncology, Wichita Falls, TX; Salvatore A. Del Prete, Hematology Oncology PC, Stamford, CT; Mark Rarick, Kaiser Permanente Northwest Region Oncology Hematology, Portland, OR; and David P. Ryan, Massachusetts General Hospital Cancer Center, Boston, MA.
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Rosen
authors.affiliation: Mitesh J. Borad, Mayo Clinic, Scottsdale; Tomislav Dragovich, Arizona Cancer Center, Tucson, AZ; Shantan G. Reddy, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA; Nathan Bahary, University of Pittsburgh Medical Center, Pittsburgh, PA; Hope E. Uronis, Duke University Medical Center, Durham, NC; Darren Sigal, Scripps Clinic, La Jolla; Peter J. Rosen, Disney Family Cancer Center, Burbank; Clarence Eng and Stew Kroll, Threshold Pharmaceuticals, South San Francisco, CA; Allen L. Cohn, Rocky Mountain Cancer Center, Denver, CO; William R. Schelman, University of Wisconsin Carbone Cancer Center, Madison, WI; Joe Stephenson Jr, Institute for Translational Oncology Research, Greenville, SC; E. Gabriela Chiorean, Indiana University Simon Cancer Center, Indianapolis, IN; Brian Ulrich, Texas Oncology, Wichita Falls, TX; Salvatore A. Del Prete, Hematology Oncology PC, Stamford, CT; Mark Rarick, Kaiser Permanente Northwest Region Oncology Hematology, Portland, OR; and David P. Ryan, Massachusetts General Hospital Cancer Center, Boston, MA.
authors.forename: Brian
authors.initials: B
authors.lastname: Ulrich
authors.affiliation: Mitesh J. Borad, Mayo Clinic, Scottsdale; Tomislav Dragovich, Arizona Cancer Center, Tucson, AZ; Shantan G. Reddy, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA; Nathan Bahary, University of Pittsburgh Medical Center, Pittsburgh, PA; Hope E. Uronis, Duke University Medical Center, Durham, NC; Darren Sigal, Scripps Clinic, La Jolla; Peter J. Rosen, Disney Family Cancer Center, Burbank; Clarence Eng and Stew Kroll, Threshold Pharmaceuticals, South San Francisco, CA; Allen L. Cohn, Rocky Mountain Cancer Center, Denver, CO; William R. Schelman, University of Wisconsin Carbone Cancer Center, Madison, WI; Joe Stephenson Jr, Institute for Translational Oncology Research, Greenville, SC; E. Gabriela Chiorean, Indiana University Simon Cancer Center, Indianapolis, IN; Brian Ulrich, Texas Oncology, Wichita Falls, TX; Salvatore A. Del Prete, Hematology Oncology PC, Stamford, CT; Mark Rarick, Kaiser Permanente Northwest Region Oncology Hematology, Portland, OR; and David P. Ryan, Massachusetts General Hospital Cancer Center, Boston, MA.
authors.forename: Tomislav
authors.initials: T
authors.lastname: Dragovich
authors.affiliation: Mitesh J. Borad, Mayo Clinic, Scottsdale; Tomislav Dragovich, Arizona Cancer Center, Tucson, AZ; Shantan G. Reddy, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA; Nathan Bahary, University of Pittsburgh Medical Center, Pittsburgh, PA; Hope E. Uronis, Duke University Medical Center, Durham, NC; Darren Sigal, Scripps Clinic, La Jolla; Peter J. Rosen, Disney Family Cancer Center, Burbank; Clarence Eng and Stew Kroll, Threshold Pharmaceuticals, South San Francisco, CA; Allen L. Cohn, Rocky Mountain Cancer Center, Denver, CO; William R. Schelman, University of Wisconsin Carbone Cancer Center, Madison, WI; Joe Stephenson Jr, Institute for Translational Oncology Research, Greenville, SC; E. Gabriela Chiorean, Indiana University Simon Cancer Center, Indianapolis, IN; Brian Ulrich, Texas Oncology, Wichita Falls, TX; Salvatore A. Del Prete, Hematology Oncology PC, Stamford, CT; Mark Rarick, Kaiser Permanente Northwest Region Oncology Hematology, Portland, OR; and David P. Ryan, Massachusetts General Hospital Cancer Center, Boston, MA.
authors.forename: Salvatore A
authors.initials: SA
authors.lastname: Del Prete
authors.affiliation: Mitesh J. Borad, Mayo Clinic, Scottsdale; Tomislav Dragovich, Arizona Cancer Center, Tucson, AZ; Shantan G. Reddy, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA; Nathan Bahary, University of Pittsburgh Medical Center, Pittsburgh, PA; Hope E. Uronis, Duke University Medical Center, Durham, NC; Darren Sigal, Scripps Clinic, La Jolla; Peter J. Rosen, Disney Family Cancer Center, Burbank; Clarence Eng and Stew Kroll, Threshold Pharmaceuticals, South San Francisco, CA; Allen L. Cohn, Rocky Mountain Cancer Center, Denver, CO; William R. Schelman, University of Wisconsin Carbone Cancer Center, Madison, WI; Joe Stephenson Jr, Institute for Translational Oncology Research, Greenville, SC; E. Gabriela Chiorean, Indiana University Simon Cancer Center, Indianapolis, IN; Brian Ulrich, Texas Oncology, Wichita Falls, TX; Salvatore A. Del Prete, Hematology Oncology PC, Stamford, CT; Mark Rarick, Kaiser Permanente Northwest Region Oncology Hematology, Portland, OR; and David P. Ryan, Massachusetts General Hospital Cancer Center, Boston, MA.
authors.forename: Mark
authors.initials: M
authors.lastname: Rarick
authors.affiliation: Mitesh J. Borad, Mayo Clinic, Scottsdale; Tomislav Dragovich, Arizona Cancer Center, Tucson, AZ; Shantan G. Reddy, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA; Nathan Bahary, University of Pittsburgh Medical Center, Pittsburgh, PA; Hope E. Uronis, Duke University Medical Center, Durham, NC; Darren Sigal, Scripps Clinic, La Jolla; Peter J. Rosen, Disney Family Cancer Center, Burbank; Clarence Eng and Stew Kroll, Threshold Pharmaceuticals, South San Francisco, CA; Allen L. Cohn, Rocky Mountain Cancer Center, Denver, CO; William R. Schelman, University of Wisconsin Carbone Cancer Center, Madison, WI; Joe Stephenson Jr, Institute for Translational Oncology Research, Greenville, SC; E. Gabriela Chiorean, Indiana University Simon Cancer Center, Indianapolis, IN; Brian Ulrich, Texas Oncology, Wichita Falls, TX; Salvatore A. Del Prete, Hematology Oncology PC, Stamford, CT; Mark Rarick, Kaiser Permanente Northwest Region Oncology Hematology, Portland, OR; and David P. Ryan, Massachusetts General Hospital Cancer Center, Boston, MA.
authors.forename: Clarence
authors.initials: C
authors.lastname: Eng
authors.affiliation: Mitesh J. Borad, Mayo Clinic, Scottsdale; Tomislav Dragovich, Arizona Cancer Center, Tucson, AZ; Shantan G. Reddy, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA; Nathan Bahary, University of Pittsburgh Medical Center, Pittsburgh, PA; Hope E. Uronis, Duke University Medical Center, Durham, NC; Darren Sigal, Scripps Clinic, La Jolla; Peter J. Rosen, Disney Family Cancer Center, Burbank; Clarence Eng and Stew Kroll, Threshold Pharmaceuticals, South San Francisco, CA; Allen L. Cohn, Rocky Mountain Cancer Center, Denver, CO; William R. Schelman, University of Wisconsin Carbone Cancer Center, Madison, WI; Joe Stephenson Jr, Institute for Translational Oncology Research, Greenville, SC; E. Gabriela Chiorean, Indiana University Simon Cancer Center, Indianapolis, IN; Brian Ulrich, Texas Oncology, Wichita Falls, TX; Salvatore A. Del Prete, Hematology Oncology PC, Stamford, CT; Mark Rarick, Kaiser Permanente Northwest Region Oncology Hematology, Portland, OR; and David P. Ryan, Massachusetts General Hospital Cancer Center, Boston, MA.
authors.forename: Stew
authors.initials: S
authors.lastname: Kroll
authors.affiliation: Mitesh J. Borad, Mayo Clinic, Scottsdale; Tomislav Dragovich, Arizona Cancer Center, Tucson, AZ; Shantan G. Reddy, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA; Nathan Bahary, University of Pittsburgh Medical Center, Pittsburgh, PA; Hope E. Uronis, Duke University Medical Center, Durham, NC; Darren Sigal, Scripps Clinic, La Jolla; Peter J. Rosen, Disney Family Cancer Center, Burbank; Clarence Eng and Stew Kroll, Threshold Pharmaceuticals, South San Francisco, CA; Allen L. Cohn, Rocky Mountain Cancer Center, Denver, CO; William R. Schelman, University of Wisconsin Carbone Cancer Center, Madison, WI; Joe Stephenson Jr, Institute for Translational Oncology Research, Greenville, SC; E. Gabriela Chiorean, Indiana University Simon Cancer Center, Indianapolis, IN; Brian Ulrich, Texas Oncology, Wichita Falls, TX; Salvatore A. Del Prete, Hematology Oncology PC, Stamford, CT; Mark Rarick, Kaiser Permanente Northwest Region Oncology Hematology, Portland, OR; and David P. Ryan, Massachusetts General Hospital Cancer Center, Boston, MA.
authors.forename: David P
authors.initials: DP
authors.lastname: Ryan
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D018450:Disease Progression; D018572:Disease-Free Survival; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009593:Nitroimidazoles / Q000008:administration & dosage; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D010752:Phosphoramide Mustards / Q000008:administration & dosage; D016016:Proportional Hazards Models; D013997:Time Factors; D016896:Treatment Outcome; D014481:United States; D000093542:Gemcitabine
chemical_list: D009593:Nitroimidazoles; D010752:Phosphoramide Mustards; C552526:TH 302; D003841:Deoxycytidine; D000093542:Gemcitabine